

Bruno Ledergerber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5689071/publications.pdf>

Version: 2024-02-01

221
papers

21,769
citations

15880

67
h-index

10679

143
g-index

225
all docs

225
docs citations

225
times ranked

17163
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet, The</i> , 2002, 360, 119-129.	6.3	1,415
2	Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. <i>PLoS Medicine</i> , 2008, 5, e203.	3.9	1,398
3	A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. <i>Science</i> , 2007, 317, 944-947.	6.0	1,136
4	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. <i>Archives of Internal Medicine</i> , 2006, 166, 1632.	4.3	1,004
5	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. <i>Lancet, The</i> , 1999, 353, 863-868.	6.3	894
6	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. <i>Lancet, The</i> , 2009, 373, 1352-1363.	6.3	676
7	Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. <i>Lancet, The</i> , 2005, 366, 378-384.	6.3	526
8	Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2011, 53, 1130-1139.	2.9	525
9	Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. <i>Aids</i> , 2005, 19, 593-601.	1.0	472
10	Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. <i>PLoS ONE</i> , 2012, 7, e44454.	1.1	456
11	AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 2220.	3.8	416
12	Common Genetic Variation and the Control of HIV-1 in Humans. <i>PLoS Genetics</i> , 2009, 5, e1000791.	1.5	377
13	Influence of Hepatitis C Virus Infection on HIV Disease Progression and Response to Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2005, 192, 992-1002.	1.9	362
14	Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. <i>Aids</i> , 2010, 24, 1667-1678.	1.0	353
15	CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years <subtitle>The Swiss HIV Cohort Study</subtitle>. <i>Archives of Internal Medicine</i> , 2003, 163, 2187.	4.3	344
16	Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. <i>Aids</i> , 1999, 13, 943-950.	1.0	335
17	Cohort Profile: The Swiss HIV Cohort Study. <i>International Journal of Epidemiology</i> , 2010, 39, 1179-1189.	0.9	322
18	Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. <i>Lancet, The</i> , 2001, 358, 1322-1327.	6.3	317

#	ARTICLE	IF	CITATIONS
19	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.	6.3	303
20	Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ÅL in HIV Type 1-Infected Individuals Receiving Potent Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2005, 41, 361-372.	2.9	285
21	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. <i>Aids</i> , 2007, 21, 1185-1197.	1.0	264
22	Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 262-270.	0.9	243
23	Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2007, 45, 111-119.	2.9	233
24	Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. <i>BMJ: British Medical Journal</i> , 1999, 319, 23-24.	2.4	208
25	Discontinuation of <i>Pneumocystis carinii</i> pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. <i>Lancet, The</i> , 1999, 353, 1293-1298.	6.3	206
26	Pulmonary Arterial Hypertension Related to HIV Infection: Improved Hemodynamics and Survival Associated with Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 38, 1178-1185.	2.9	186
27	Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 413-423.	0.6	172
28	Molecular Epidemiology Reveals Long-Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. <i>Journal of Infectious Diseases</i> , 2010, 201, 1488-1497.	1.9	172
29	High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. <i>Aids</i> , 2010, 24, 1127-1134.	1.0	159
30	Discontinuation of Secondary Prophylaxis against <i>Pneumocystis carinii</i> Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2001, 344, 168-174.	13.9	155
31	Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIV-Infected Patients with Anti-HCV Antibodies in Europe. <i>Journal of Infectious Diseases</i> , 2008, 198, 1337-1344.	1.9	145
32	Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. <i>Aids</i> , 2008, 22, 2135-2141.	1.0	145
33	Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 36-43.	0.9	142
34	The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics. <i>International Journal of Public Health</i> , 1994, 39, 387-394.	2.7	138
35	A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2002, 185, 1251-1260.	1.9	132
36	Role of retroviral restriction factors in the interferon-Î±-mediated suppression of HIV-1 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3035-3040.	3.3	129

#	ARTICLE	IF	CITATIONS
37	Treatment Modification in Human Immunodeficiency Virus-Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008. <i>Archives of Internal Medicine</i> , 2010, 170, 57.	4.3	127
38	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 532-539.	2.9	127
39	The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy. <i>Archives of Internal Medicine</i> , 2005, 165, 416.	4.3	124
40	Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2002, 137, 239.	2.0	122
41	Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. <i>Aids</i> , 2007, 21, 2223-2229.	1.0	117
42	Association of Noncirrhotic Portal Hypertension in HIV-Infected Persons and Antiretroviral Therapy with Didanosine: A Nested Case-Control Study. <i>Clinical Infectious Diseases</i> , 2009, 49, 626-635.	2.9	117
43	A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2002, 185, 178-187.	1.9	116
44	Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment; A Comparison of Different Regimen Types. <i>Archives of Internal Medicine</i> , 2007, 167, 1782.	4.3	116
45	Public-Health and Individual Approaches to Antiretroviral Therapy: Township South Africa and Switzerland Compared. <i>PLoS Medicine</i> , 2008, 5, e148.	3.9	113
46	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. <i>Aids</i> , 2002, 16, 1967-1969.	1.0	107
47	Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 Å– 106/l. <i>Aids</i> , 2002, 16, 1371-1381.	1.0	105
48	Modeling the Influence ofAPOC3, APOE,andTNFPolymorphisms on the Risk of Antiretroviral Therapy-Associated Lipid Disorders. <i>Journal of Infectious Diseases</i> , 2005, 191, 1419-1426.	1.9	105
49	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 217-230.	0.7	104
50	Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. <i>Lancet</i> , The, 2003, 362, 877-878.	6.3	101
51	Virological rebound after suppression on highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 1741-1751.	1.0	99
52	Durability and Outcome of Initial Antiretroviral Treatments Received during 2000-2005 by Patients in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2008, 197, 1685-1694.	1.9	95
53	Optimal Length of Cultivation Time for Isolation of <i>Propionibacterium acnes</i> in Suspected Bone and Joint Infections Is More than 7 Days. <i>Journal of Clinical Microbiology</i> , 2016, 54, 3043-3049.	1.8	90
54	Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 246-257.	1.9	89

#	ARTICLE	IF	CITATIONS
55	Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-infection. <i>Clinical Infectious Diseases</i> , 2010, 50, 502-511.	2.9	88
56	Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 28-35.	0.9	86
57	Different Patterns of Inappropriate Antimicrobial Use in Surgical and Medical Units at a Tertiary Care Hospital in Switzerland: A Prevalence Survey. <i>PLoS ONE</i> , 2010, 5, e14011.	1.1	85
58	Effect of Acetazolamide and AutoCPAP Therapy on Breathing Disturbances Among Patients With Obstructive Sleep Apnea Syndrome Who Travel to Altitude. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2390.	3.8	84
59	Frequency and Determinants of Unprotected Sex among HIV-Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2010, 51, 1314-1322.	2.9	83
60	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study. <i>Lancet</i> , The, 2010, 376, 340-345.	6.3	82
61	Incidence and Predictors of Virologic Failure of Antiretroviral Triple-Drug Therapy in a Community-Based Cohort. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1631-1638.	0.5	79
62	Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. <i>Aids</i> , 2012, 26, 193-205.	1.0	78
63	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study. <i>Aids</i> , 2003, 17, 2237-2244.	1.0	76
64	Treatment-Naïve Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 285-294.	2.9	75
65	The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland. <i>Journal of Infectious Diseases</i> , 2011, 204, 1095-1103.	1.9	74
66	Human Immunodeficiency Virus Type 1 p24 Concentration Measured by Boosted ELISA of Heat-Denatured Plasma Correlates with Decline in CD4 Cells, Progression to AIDS, and Survival: Comparison with Viral RNA Measurement. <i>Journal of Infectious Diseases</i> , 2000, 181, 1280-1287.	1.9	73
67	The HIV care cascade in Switzerland. <i>Aids</i> , 2015, 29, 2509-2515.	1.0	72
68	Factors Associated with the Development of Opportunistic Infections in HIV-Infected Adults with High CD4+Cell Counts: A EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 633-641.	1.9	70
69	Causality, Mediation and Time: A Dynamic Viewpoint. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2012, 175, 831-861.	0.6	70
70	Correlation between case mix index and antibiotic use in hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 837-842.	1.3	66
71	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. <i>Annals of Internal Medicine</i> , 2021, 174, 758-767.	2.0	66
72	Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. <i>Aids</i> , 2001, 15, 2385-2395.	1.0	61

#	ARTICLE	IF	CITATIONS
73	A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. <i>Statistics in Medicine</i> , 2010, 29, 2757-2768.	0.8	61
74	Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu040.	0.4	61
75	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015, 212, 28-38.	1.9	61
76	Effect of Individual Cognitive Behaviour Intervention on Adherence to Antiretroviral Therapy: Prospective Randomized Trial. <i>Antiviral Therapy</i> , 2004, 9, 85-95.	0.6	61
77	Sex differences in HIV-1 viral load and progression to AIDS. <i>Lancet, The</i> , 1999, 353, 589.	6.3	60
78	Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. <i>Gut</i> , 2011, 60, 1506-1519.	6.1	60
79	HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. <i>Aids</i> , 2008, 22, 469-479.	1.0	59
80	Regional Differences in Use of Antiretroviral Agents and Primary Prophylaxis in 3122 European HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 16, 153-160.	0.3	58
81	Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy. <i>Antiviral Therapy</i> , 2005, 10, 791-802.	0.6	55
82	Estimating Loss to Follow-Up in HIV-Infected Patients on Antiretroviral Therapy: The Effect of the Competing Risk of Death in Zambia and Switzerland. <i>PLoS ONE</i> , 2011, 6, e27919.	1.1	54
83	Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B. <i>Clinical Infectious Diseases</i> , 2011, 53, 1143-1152.	2.9	53
84	Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus-Infected Patients with Very Low CD4 Cell Counts. <i>Journal of Infectious Diseases</i> , 2002, 186, 189-197.	1.9	52
85	Stable virulence levels in the HIV epidemic of Switzerland over two decades. <i>Aids</i> , 2006, 20, 889-894.	1.0	52
86	Reasons for late presentation to HIV care in Switzerland. <i>Journal of the International AIDS Society</i> , 2015, 18, 20317.	1.2	52
87	Survival in HIV infection: do sex and category of transmission matter?. <i>Aids</i> , 1994, 8, 1307-1313.	1.0	49
88	Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 457-463.	0.9	49
89	Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. <i>Aids</i> , 2008, 22, 767-775.	1.0	48
90	Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. <i>European Heart Journal</i> , 2018, 39, 2147-2154.	1.0	47

#	ARTICLE	IF	CITATIONS
91	A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2194-e2202.	2.9	47
92	Stratification of cumulative antibiograms in hospitals for hospital unit, specimen type, isolate sequence and duration of hospital stay. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1451-1461.	1.3	46
93	High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. <i>Journal of Hepatology</i> , 2015, 63, 573-580.	1.8	46
94	Importance of Mental Health Assessment in HIV-Infected Outpatients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 240-249.	0.9	44
95	Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009, 48, 979-987.	2.9	43
96	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	4.3	42
97	Antiretroviral Drug-Related Liver Mortality Among HIV-Positive Persons in the Absence of Hepatitis B or C Virus Coinfection: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 870-879.	2.9	42
98	HIV-1 p24 Antigen Is a Significant Inverse Correlate of CD4 T-Cell Change in Patients With Suppressed Viremia Under Long-Term Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 292-299.	0.9	41
99	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 119-127.	4.6	41
100	Intestinal Infection Due to Enteroaggregative <i>Escherichia coli</i> among Human Immunodeficiency Virus-Infected Persons. <i>Journal of Infectious Diseases</i> , 2000, 182, 1540-1544.	1.9	40
101	Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. <i>Aids</i> , 2002, 16, 747-755.	1.0	40
102	Frequency of and Risk Factors for Depression among Participants in the Swiss HIV Cohort Study (SHCS). <i>PLoS ONE</i> , 2015, 10, e0140943.	1.1	40
103	Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy The Swiss HIV Cohort Study. <i>Aids</i> , 2001, 15, 1793-1800.	1.0	39
104	Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. <i>Aids</i> , 2006, 20, 1141-1150.	1.0	39
105	Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. <i>Aids</i> , 2007, 21, 1867-1875.	1.0	38
106	Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 621-628.	5.1	38
107	Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv108.	0.4	38
108	Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis. <i>Antiviral Therapy</i> , 2006, 11, 567-574.	0.6	38

#	ARTICLE	IF	CITATIONS
109	Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infection. <i>Aids</i> , 1998, 12, 2253-2260.	1.0	36
110	Risk Factors for and Outcome of Hyperlactatemia in HIV-Infected Persons: Is There a Need for Routine Lactate Monitoring?. <i>Clinical Infectious Diseases</i> , 2005, 41, 721-728.	2.9	36
111	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. <i>International Journal of Epidemiology</i> , 2014, 43, 887-896.	0.9	36
112	Factors Associated with the Emergence of K65R in Patients with HIV-1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1299-1309.	2.9	35
113	HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 1077-1086.	0.6	35
114	Long-term exposure to combination antiretroviral therapy and risk of death from specific causes. <i>Aids</i> , 2012, 26, 315-323.	1.0	35
115	Eligibility for and Outcome of Hepatitis C Treatment of HIV-Coinfected Individuals in Clinical Practice: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2006, 11, 131-142.	0.6	35
116	Causes of death in HIV infection. <i>Aids</i> , 2004, 18, 2333-2337.	1.0	34
117	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>International Journal of Epidemiology</i> , 2012, 41, 1807-1820.	0.9	34
118	Co-Trimoxazole Prophylaxis Is Associated with Reduced Risk of Incident Tuberculosis in Participants in the Swiss HIV Cohort Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2363-2368.	1.4	34
119	Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw809.	2.9	34
120	Delayed Sputum Culture Conversion in Tuberculosisâ€“Human Immunodeficiency Virusâ€“Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. <i>Clinical Infectious Diseases</i> , 2018, 67, 708-716.	2.9	34
121	HIV Cohort Collaborations: Proposal for Harmonization of Data Exchange. <i>Antiviral Therapy</i> , 2004, 9, 631-633.	0.6	33
122	Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatmentâ€“Naive Individuals Starting Modern Therapy Combinations. <i>Clinical Infectious Diseases</i> , 2012, 54, 131-140.	2.9	32
123	The role of FDG PET/CT in therapy control of aortic graft infection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1987-1997.	3.3	32
124	Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0142923.	1.1	32
125	Randomized, Placebo-Controlled Trial of Chinese Herb Therapy for HIV-1â€“Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 22, 56.	0.3	31
126	Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a caseâ€“control study from the Swiss HIV Cohort. <i>Aids</i> , 2002, 16, 381-385.	1.0	31

#	ARTICLE	IF	CITATIONS
127	Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection. Archives of Internal Medicine, 2012, 172, 1313.	4.3	31
128	Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. PLoS ONE, 2007, 2, e173.	1.1	31
129	Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Aids, 2000, 14, 2145-2151.	1.0	30
130	Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland. Aids, 2015, 29, 231-238.	1.0	30
131	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. Aids, 2005, 19, 1987-1994.	1.0	29
132	A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study. HIV Clinical Trials, 2011, 12, 109-117.	2.0	29
133	Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich. BMC Infectious Diseases, 2014, 14, 607.	1.3	29
134	Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity <i>In Vivo</i> . Journal of Virology, 2014, 88, 763-767.	1.5	29
135	Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. Aids, 2000, 14, 1409-1412.	1.0	28
136	Antiretroviral Treatment and Osteonecrosis in Patients of the Swiss HIV Cohort Study: A Nested Case-Control Study. AIDS Research and Human Retroviruses, 2004, 20, 909-915.	0.5	28
137	African descent is associated with slower CD4 cell count decline in treatment-naïve patients of the Swiss HIV Cohort Study. Aids, 2009, 23, 1269-1276.	1.0	28
138	Comparing diagnostic accuracy of 18F-FDG-PET/CT, contrast enhanced CT and combined imaging in patients with suspected vascular graft infections. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1359-1368.	3.3	28
139	Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV-1 Reverse Transcriptase. Journal of Infectious Diseases, 2010, 201, 1054-1062.	1.9	27
140	Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. Aids, 2004, 18, 1795-1804.	1.0	26
141	Impact of Single Nucleotide Polymorphisms and of Clinical Risk Factors on New-Onset Diabetes Mellitus in HIV-Infected Individuals. Clinical Infectious Diseases, 2010, 51, 1090-1098.	2.9	26
142	HIV-1 Reverse Transcriptase Connection Domain Mutations: Dynamics of Emergence and Implications for Success of Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2010, 51, 620-628.	2.9	26
143	Diagnostic Accuracy of PET/CT and Contrast Enhanced CT in Patients With Suspected Infected Aortic Aneurysms. European Journal of Vascular and Endovascular Surgery, 2020, 59, 972-981.	0.8	26
144	Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Aids, 1999, 13, 1587.	1.0	24

#	ARTICLE	IF	CITATIONS
145	Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. <i>Antiviral Therapy</i> , 2003, 8, 127-136.	0.6	24
146	Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 24-31.	0.9	23
147	Inadequate Perioperative Prophylaxis and Postsurgical Complications After Graft Implantation Are Important Risk Factors for Subsequent Vascular Graft Infections: Prospective Results From the Vascular Graft Infection Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 621-630.	2.9	23
148	Impact of Genotypic Resistance Testing on Selection of Salvage Regimen in Clinical Practice. <i>Antiviral Therapy</i> , 2003, 8, 443-454.	0.6	23
149	Regional survival differences across Europe In HIV-positive people: the EuroSIDA study. <i>Aids</i> , 1999, 13, 2281-2288.	1.0	22
150	A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. <i>International Journal of Epidemiology</i> , 2007, 36, 1309-1318.	0.9	22
151	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. <i>Medicine (United States)</i> , 2016, 95, e5094.	0.4	22
152	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 637-645.	1.9	22
153	Editor's Choice " Validation of the Management of Aortic Graft Infection Collaboration (MAGIC) Criteria for the Diagnosis of Vascular Graft/Endograft Infection: Results from the Prospective Vascular Graft Cohort Study. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 62, 251-257.	0.8	22
154	Risk factors for urinary tract infections due to ciprofloxacin-resistant <i>Escherichia coli</i> in a tertiary care urology department in Switzerland. <i>Swiss Medical Weekly</i> , 2010, 140, w13059.	0.8	21
155	Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis. <i>AIDS and Behavior</i> , 2012, 16, 245-255.	1.4	20
156	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw009.	0.4	20
157	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. <i>PLoS ONE</i> , 2015, 10, e0133028.	1.1	18
158	Impact of Previous Virological Treatment Failures and Adherence on the Outcome of Antiretroviral Therapy in 2007. <i>PLoS ONE</i> , 2009, 4, e8275.	1.1	18
159	Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 53, 464-471.	0.9	17
160	Noncirrhotic Portal Hypertension and Didanosine: A Re-Analysis. <i>Clinical Infectious Diseases</i> , 2011, 52, 154-155.	2.9	17
161	Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. <i>PLoS ONE</i> , 2012, 7, e50307.	1.1	16
162	The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. <i>CMAJ Open</i> , 2014, 2, E318-E329.	1.1	16

#	ARTICLE	IF	CITATIONS
163	Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. <i>Journal of Infectious Diseases</i> , 2014, 210, 1555-1561.	1.9	16
164	A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw089.	0.4	16
165	HIV cohort collaborations: proposal for harmonization of data exchange. <i>Antiviral Therapy</i> , 2004, 9, 631-3.	0.6	16
166	Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients. <i>PLoS ONE</i> , 2012, 7, e37983.	1.1	15
167	Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study. <i>AIDS Research and Therapy</i> , 2015, 12, 4.	0.7	15
168	Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. <i>Aids</i> , 2004, 18, 2213-2215.	1.0	14
169	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 294-299.	0.9	13
170	Quantification of In Vivo Replicative Capacity of HIV-1 in Different Compartments of Infected Cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 397-404.	0.9	12
171	Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 563-570.	0.6	12
172	Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study. <i>Statistics in Medicine</i> , 2011, 30, 2947-2958.	0.8	12
173	CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. <i>Aids</i> , 2013, 27, 907-918.	1.0	12
174	PET/CT helps to determine treatment duration in patients with resected as well as inoperable alveolar echinococcosis. <i>Parasitology International</i> , 2021, 83, 102356.	0.6	12
175	Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level. <i>PLoS ONE</i> , 2013, 8, e74024.	1.1	12
176	No Longitudinal Mitochondrial DNA Sequence Changes in HIV-infected Individuals With and Without Lipoatrophy. <i>Journal of Infectious Diseases</i> , 2011, 203, 620-624.	1.9	11
177	Treatment modification in HIV-Infected individuals starting antiretroviral therapy between 2011 and 2014. <i>Journal of the International AIDS Society</i> , 2014, 17, 19768.	1.2	11
178	Perioperative Antibiotic Prophylaxis Has No Effect on Time to Positivity and Proportion of Positive Samples: a Cohort Study of 64 <i>Cutibacterium acnes</i> Bone and Joint Infections. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	11
179	Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 70, 884-889.	2.9	11
180	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , 2004, 9, 263-274.	0.6	11

#	ARTICLE	IF	CITATIONS
181	Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx177.	0.4	10
182	A Longitudinal Analysis of Healthcare Costs after Treatment Optimization following Genotypic Antiretroviral Resistance Testing: Does Resistance Testing pay off?. <i>Antiviral Therapy</i> , 2006, 11, 305-314.	0.6	10
183	Predictors for the Emergence of the 2 Multi-nucleoside/nucleotide Resistance Mutations 69 Insertion and Q151M and their Impact on Clinical Outcome in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 791-797.	1.9	9
184	Polymorphic Mutations Associated With the Emergence of the Multinucleoside/Tide Resistance Mutations 69 Insertion and Q151M. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 105-112.	0.9	9
185	Prevalence and Predictors for Homo- and Heterosubtypic Antibodies Against Influenza A Virus. <i>Clinical Infectious Diseases</i> , 2014, 59, 1386-1393.	2.9	9
186	Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. <i>BMJ Open</i> , 2017, 7, e014679.	0.8	9
187	PET/CT in therapy control of infective native aortic aneurysms. <i>Scientific Reports</i> , 2021, 11, 5065.	1.6	9
188	Predictive Cross-validation for the Choice of Linear Mixed-effects Models with Application to Data from the Swiss HIV Cohort Study. <i>Biometrics</i> , 2012, 68, 53-61.	0.8	8
189	Difference in factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19667.	1.2	8
190	Dynamic Models for Estimating the Effect of HAART on CD4 in Observational Studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study. <i>Biometrics</i> , 2017, 73, 294-304.	0.8	8
191	The influence of human genetic variation on Epstein-Barr virus sequence diversity. <i>Scientific Reports</i> , 2021, 11, 4586.	1.6	8
192	Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. <i>Antiviral Therapy</i> , 2003, 8, 443-54.	0.6	8
193	Effect of Hepatitis C Treatment on CD4 ⁺ T-C E I L Counts And The Risk Of Death In HIV-HCV-Coinfected Patients: The Cohere Collaboration. <i>Antiviral Therapy</i> , 2012, 17, 1541-1550.	0.6	7
194	Predictors of CD4 ⁺ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	1.9	7
195	Role of MicroRNA Modulation in the Interferon-Î±/Ribavirin Suppression of HIV-1 In Vivo. <i>PLoS ONE</i> , 2014, 9, e109220.	1.1	7
196	Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape. <i>Infection</i> , 2016, 44, 521-529.	2.3	7
197	High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 135-138.	1.3	7
198	Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. <i>Clinical Infectious Diseases</i> , 2019, 70, 890-897.	2.9	7

#	ARTICLE	IF	CITATIONS
199	Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIV. <i>Clinical Infectious Diseases</i> , 2021, 73, e2070-e2076.	2.9	7
200	Rapid Progression of Kidney Dysfunction in People Living With HIV: Use of Polygenic and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Scores. <i>Journal of Infectious Diseases</i> , 2020, 223, 2145-2153.	1.9	7
201	Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: EuroSIDA Study. <i>Antiviral Therapy</i> , 2004, 9, 787-800.	0.6	7
202	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv257.	1.3	6
203	Impact of unknown incidental findings in PET/CT examinations of patients with proven or suspected vascular graft or endograft infections. <i>Scientific Reports</i> , 2021, 11, 13747.	1.6	6
204	Neurocognitive course at two-year follow-up in the neurocognitive assessment in the metabolic and aging cohort (NAMACO) study. <i>Aids</i> , 2021, Publish Ahead of Print, 2469-2480.	1.0	6
205	Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw101.	0.4	5
206	Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1597-1604.	2.9	5
207	Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0133879.	1.1	5
208	Accounting for baseline differences and measurement error in the analysis of change over time. <i>Statistics in Medicine</i> , 2014, 33, 2-16.	0.8	4
209	Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT Angiography. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa438.	0.4	4
210	A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?. <i>Antiviral Therapy</i> , 2006, 11, 305-14.	0.6	4
211	Reply to Chang and Garcia-Pagan. <i>Clinical Infectious Diseases</i> , 2010, 50, 128-129.	2.9	3
212	A Lower CD4 Count Predicts Most Causes of Death except Cardiovascular Deaths. The Austrian HIV Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12532.	1.2	3
213	Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. <i>Journal of Infectious Diseases</i> , 2022, 225, 1581-1591.	1.9	3
214	HIV-1 progression in hepatitis-C-infected drug users. <i>Lancet, The</i> , 2001, 357, 1363.	6.3	2
215	Estimating the treatment effect on the treated under time-dependent confounding in an application to the Swiss HIV Cohort Study. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2018, 67, 103-125.	0.5	2
216	Open wounds and rifampicin therapy are associated with rifampicin resistance among staphylococcal vascular graft/endograft infections. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab041.	0.9	2

#	ARTICLE	IF	CITATIONS
217	Impact of Delaying Antiretroviral Treatment During Primary Human Immunodeficiency Virus Infection on Telomere Length. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	2
218	Response to Calcagno Comment on "Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid" <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, e14-e15.	0.9	1
219	Reply to Kuniholm et al. <i>Clinical Infectious Diseases</i> , 2010, 50, 1546-1547.	2.9	0
220	IF11. Good Early Results of Negative Pressure Wound Nonexcisional Treatment for Prosthetic Graft Infection Are Durable: It Is a Game Changer. <i>Journal of Vascular Surgery</i> , 2018, 67, e62.	0.6	0
221	Validation of the Management of Aortic Graft Infection Collaboration (MAGIC) Criteria for the Diagnosis of Vascular Graft/Endograft Infection: Results from the Prospective Vascular Graft Cohort Study. <i>Journal of Vascular Surgery</i> , 2021, 74, 1046.	0.6	0